192 related articles for article (PubMed ID: 34689520)
1. [Daratumumab for the treatment of primary systemic amyloidosis: a multicenter retrospective analysis].
Liu Y; Huang XH; Duan WB; Fang BJ; Huang DP; Zhang YH; Xu L; Zhang HY; Zhang H; Wen L; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2021 Nov; 60(11):987-992. PubMed ID: 34689520
[No Abstract] [Full Text] [Related]
2. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].
Shen KN; Miao HL; Gao YJ; Cao XX; Zhou DB; Su W; Li J
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):31-34. PubMed ID: 35231990
[No Abstract] [Full Text] [Related]
4. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Roussel M; Merlini G; Chevret S; Arnulf B; Stoppa AM; Perrot A; Palladini G; Karlin L; Royer B; Huart A; Macro M; Morel P; Frenzel L; Touzeau C; Boyle E; Dorvaux V; Le Bras F; Lavergne D; Bridoux F; Jaccard A
Blood; 2020 Apr; 135(18):1531-1540. PubMed ID: 32108228
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
[TBL] [Abstract][Full Text] [Related]
6. Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.
Shen KN; Miao HL; Zhang CL; Feng J; Zhang L; Cao XX; Zhou DB; Wei S; Li J
Leuk Lymphoma; 2021 Apr; 62(4):874-882. PubMed ID: 33215569
[TBL] [Abstract][Full Text] [Related]
7. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
[TBL] [Abstract][Full Text] [Related]
8. First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience.
Jeryczynski G; Antlanger M; Duca F; Binder-Rodriguez C; Reiter T; Simonitsch-Klupp I; Bonderman D; Kain R; Krauth MT; Agis H
ESMO Open; 2021 Apr; 6(2):100065. PubMed ID: 33667762
[TBL] [Abstract][Full Text] [Related]
9. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC; Brodermann MH; Blakeney IJ; Mahmood S; Sachchithanantham S; Ravichandran S; Law S; Lachmann HJ; Whelan CJ; Popat R; Rabin N; Yong K; Kyriakou C; Shah R; Cheesman S; Worthington S; Hawkins P; Gillmore JD; Wechalekar AD
Amyloid; 2020 Sep; 27(3):200-205. PubMed ID: 32408823
[No Abstract] [Full Text] [Related]
10. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
[TBL] [Abstract][Full Text] [Related]
11. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
[TBL] [Abstract][Full Text] [Related]
13. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature.
Lecumberri R; Krsnik I; Askari E; Sirvent M; González-Pérez MS; Escalante F; Pradillo V; Tamariz LE; Cánovas V; Alegre A; Gironella M; González-García ME; Infante MS; Lakhwani S; Martínez-Bilbao C; Dourdil V; Ramírez-Payer Á; Sarrá J; Cibeira MT
Amyloid; 2020 Sep; 27(3):163-167. PubMed ID: 32106714
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
[TBL] [Abstract][Full Text] [Related]
15. First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy.
Chakraborty R; Rosenbaum C; Kaur G; Bhutani D; Radhakrishnan J; Mapara MY; Maurer M; Lentzsch S
Br J Haematol; 2023 Jun; 201(5):913-916. PubMed ID: 36896578
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
Sanchorawala V; Sarosiek S; Schulman A; Mistark M; Migre ME; Cruz R; Sloan JM; Brauneis D; Shelton AC
Blood; 2020 Apr; 135(18):1541-1547. PubMed ID: 31978210
[TBL] [Abstract][Full Text] [Related]
17. [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].
Wang LM; Wang TT; Tian Y; Zhao L; Yang XC; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):47-53. PubMed ID: 32023754
[No Abstract] [Full Text] [Related]
18. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
19. Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis.
Jimenez-Zepeda VH; Lee H; McCulloch S; Tay J; Duggan P; Neri P; Bahlis N
Amyloid; 2021 Sep; 28(3):182-188. PubMed ID: 34096429
[TBL] [Abstract][Full Text] [Related]
20. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
